Ustekinumab
Mechanism :
Human monoclonal antibody that binds to and interferes with the proinflammatory cytokines, interleukin (IL)-12 and IL-23.
Indication :
- Crohn’s disease
- Plaque psoriasis
Contraindications :
Clinically significant hypersensitivity to ustekinumab or any component of the formulation.
Dosing :
Plaque psoriasis:
Children ≥12 years and Adolescents:
<60 kg: 0.75 mg/kg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.
≥60 kg to ≤100 kg: 45 mg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.
>100 kg: 90 mg SC at day 1 and then after 4 weeks, and then every 12 weeks thereafter.
Adverse Effect :
Antibody development, Infection, Nasopharyngitis, Headache, fatigue, dizziness, Erythema at injection site.
Interaction :
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical).
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.
Infliximab: Ustekinumab may enhance the immunosuppressive effect of Infliximab.
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.
Vaccines (Live): Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.
Hepatic Dose :
No dose adjustment recommended.